Xiaofeng Ye Sells 5,667 Shares of Adlai Nortye (NASDAQ:ANL) Stock

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) CFO Xiaofeng Ye sold 5,667 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $14.25, for a total value of $80,754.75. Following the transaction, the chief financial officer directly owned 147,757 shares in the company, valued at $2,105,537.25. This trade represents a 3.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xiaofeng Ye also recently made the following trade(s):

• On Monday, August 24th, Xiaofeng Ye sold 6,000 shares of Adlai Nortye stock. The stock was sold at an average price of $13.98, for a total value of $83,880.00.

Adlai Nortye Trading Down 4.9%

NASDAQ ANL opened at $14.32 on Friday. Adlai Nortye Ltd. Sponsored ADR has a 1-year low of $0.88 and a 1-year high of $17.25. The stock has a 50-day moving average of $12.09 and a 200-day moving average of $11.19. The company has a debt-to-equity ratio of 0.04, a current ratio of 9.55 and a quick ratio of 0.65.

Wall Street Analysts Forecast Growth

ANL has been the subject of several recent research reports. Cantor Fitzgerald started coverage on Adlai Nortye in a research report on Monday, June 22nd. They issued an “overweight” rating for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Adlai Nortye in a report on Tuesday, July 14th. Oppenheimer started coverage on shares of Adlai Nortye in a research note on Thursday, May 28th. They issued an “outperform” rating and a $32.00 target price on the stock. Wall Street Zen upgraded shares of Adlai Nortye from a “hold” rating to a “buy” rating in a report on Saturday, August 22nd. Finally, JonesTrading assumed coverage on shares of Adlai Nortye in a research report on Thursday, May 14th. They set a “buy” rating and a $22.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $24.25.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Seven Fleet Capital Management LP bought a new position in Adlai Nortye during the 2nd quarter valued at approximately $1,302,000. Braidwell LP bought a new stake in shares of Adlai Nortye in the 2nd quarter worth approximately $9,145,000. Boone Capital Management LLC bought a new stake in shares of Adlai Nortye in the 2nd quarter worth approximately $2,971,000. ADAR1 Capital Management LLC purchased a new position in shares of Adlai Nortye during the first quarter valued at approximately $816,000. Finally, Affinity Asset Advisors LLC purchased a new position in shares of Adlai Nortye during the first quarter valued at approximately $1,140,000. Institutional investors own 35.21% of the company’s stock.

Adlai Nortye Company Profile

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.